Daewoong Pharmaceutical said Tuesday that it plans to launch TerahVax Korea's Vivotif, an oral typhoid fever vaccine, in the first half of this year after securing domestic rights for the drug.
|TerahVax’s typhoid fever vaccine Vivotif|
Vivotif is the only typhoid vaccine in Korea that has received approval from the U.S. Food and Drug Administration and the European Medicines Agency. The vaccine’s main component consists of a live salmonella typhoid Ty21a strain.
Typhoid fever is an acute infectious disease of the digestive system transmitted through contaminated water or food. The disease has a poor prognosis and is highly contagious, and the government designated it as a class-1 infectious disease.
According to the Korea Centers for Disease Control and Prevention, the average annual number of typhoid fever patients in the past five years was 120 but has since increased to more than twice to 247 in 2018.
Notably, up to 100 travelers who visited South Asian and Southeast Asian countries, including India, Laos, and the Philippines, contracted the disease.
“By supplying high-quality vaccine medicines to more than 30 million outbound travelers annually, we will contribute to preventing infectious diseases by expanding the vaccine market,” Daewoong CEO Jeon Seung-ho said.
TerahVax Korea President Jun Young-jin also said, “We expect Daewoong will raise awareness and vaccination rate of Korean travelers.”
According to IQVIA, a market research firm, the domestic anti-typhoid vaccine market is estimated at 300 million won ($265,360) in 2018.
<© Korea Biomedical Review, All rights reserved.>